Research Triangle Park, NC – According to filings with the U.S. Securities and Exchange Commission, T3D Therapeutics is raising $7,500,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, John Didsbury played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About T3D Therapeutics
T3D Therapeutics mission is to develop its lead drug product candidate, T3D-959, as a potential First-in-Class and Best-in-Class disease-modifying, breakthrough medicine for the treatment of Alzheimers disease with the potential to slow, stop or reverse the course of the disease. The Company is also seeking to maximize the therapeutic utility of T3D-959 and has initiated pre-clinical studies in Huntingtons Disease models.

To learn more about T3D Therapeutics, visit http://www.t3dtherapeutics.com/

Contact:
John Didsbury, President and Chief Executive Officer
919-949-0517

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved